Placebo and Nocebo Effects Are Defined by Opposite Opioid and Dopaminergic Responses 2008 (Claims Objective Proof of Placebo)

DigitalDrifter · Aug 22, 2023

Full article available: https://jamanetwork.com/journals/jamapsychiatry/fullarticle/482600

Results Placebo-induced activation of opioid neurotransmission was detected in the anterior cingulate, orbitofrontal and insular cortices, nucleus accumbens, amygdala, and periaqueductal gray matter. Dopaminergic activation was observed in the ventral basal ganglia, including the nucleus accumbens. Regional DA and opioid activity were associated with the anticipated and subjectively perceived effectiveness of the placebo and reductions in continuous pain ratings. High placebo responses were associated with greater DA and opioid activity in the nucleus accumbens. Nocebo responses were associated with a deactivation of DA and opioid release. Nucleus accumbens DA release accounted for 25% of the variance in placebo analgesic effects.
Click to expand...

Log in or Sign up

Placebo and Nocebo Effects Are Defined by Opposite Opioid and Dopaminergic Responses 2008 (Claims Objective Proof of Placebo)

DigitalDrifter Senior Member (Voting Rights)

Share This Page

Log in or Sign up

Placebo and Nocebo Effects Are Defined by Opposite Opioid and Dopaminergic Responses 2008 (Claims Objective Proof of Placebo)

DigitalDrifter Senior Member (Voting Rights)

Share This Page

Useful Searches